Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India |
Doval, Dinesh Chandra
(Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre)
Sharma, Anila (Department of Laboratory Services, Rajiv Gandhi Cancer Institute & Research Centre) Sinha, Rupal (Department of Research, Rajiv Gandhi Cancer Institute & Research Centre) Kumar, Kapil (Department of Surgical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) Dewan, Ajay Kumar (Department of Surgical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) Chaturvedi, Harit (Department of Surgical Oncology, MAX Hospital) Batra, Ullas (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) Talwar, Vineet (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) Gupta, Sunil Kumar (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) Singh, Shailendra (Auriga Life Sciences) Bhole, Vidula (Episolutions Consultancy Services) Mehta, Anurag (Department of Laboratory Services, Rajiv Gandhi Cancer Institute & Research Centre) |
1 | Ambroise M, Ghosh M, Mallikarjuna VS, et al (2011). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev, 12, 625-9. |
2 | Babu GR, Lakshmi SB, Thiyagarajan JA (2013). Epidemiological correlates of breast cancer in South India. Asian Pac J Cancer Prev, 14, 5077-83. DOI ScienceOn |
3 | Badve S, Dabbs DJ, Schnitt SJ, et al (2011). Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol, 24, 157-67. DOI ScienceOn |
4 | Basu S, Chen W, Tchou J, et al (2008). Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer, 112, 995-1000. DOI |
5 | D'Souza ND, Murthy NS, Aras RY (2013). Projection of cancer incident cases for India -till 2026. Asian Pac J Cancer Prev, 14, 4379-86. DOI ScienceOn |
6 | Dogra A, Doval DC, Sardana M, et al (2014). Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. Asian Pac J Cancer Prev, 15, 10577-83. |
7 | Dowsett M, Houghton J, Iden C, et al (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol, 17, 818-26. DOI |
8 | Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI |
9 | Group EBCTC (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-67. DOI |
10 | J Ferlay ISI, M Ervik, R Dikshit, et al (2012). Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [Online]. [Accessed 15 April 2015]. |
11 | Manjunath S, Prabhu JS, Kaluve R, et al (2011). Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype? Indian J Surg Oncol, 2, 122-5. DOI |
12 | Munjal K, Ambaye A, Evans MF, et al (2009). Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev, 10, 773-8. |
13 | Patil AV, Bhamre RS, Singhai R, et al (2011a). Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women. Breast Cancer (Dove Med Press), 3, 27-33. |
14 | Patil VW, Singhai R, Patil AV, et al (2011b). Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer (Dove Med Press), 3, 9-19. |
15 | Perez EA, Romond EH, Suman VJ, et al (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 29, 3366-73. DOI |
16 | Vaidyanathan K, Kumar P, Reddy CO, et al (2010). ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer, 47, 8-15. DOI |
17 | Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. DOI |
18 | Shet T, Agrawal A, Nadkarni M, et al (2009). Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol, 52, 171-4. DOI |
19 | Singhai R, Patil V, Patil A (2011). Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women. Asian Pac J Cancer Prev, 12, 179-83. |
20 | Zhang SJ, Hu Y, Qian HL, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40. DOI ScienceOn |